Adverse Outcomes Are Increased with Exposure to Added Combinations of Infant Vaccines


  • Karl Jablonowski Children's Health Defense
  • Brian Hooker Children's Health Defense



infant vaccine combinations, adverse effects, adverse outcome discovery, DTaP, suspected infection, rotavirus vaccine, polio vaccine, pneumococcal vaccine, HIB vaccine, developmental disorders, developmental diseases, respiratory disease, hepatitis B vaccine


This study evaluates 1,542,076 vaccine combinations administered to infants (less than 1 year of age at time of vaccination) between July 1st, 1991 and May 31st, 2011. All patients received a minimum of DTaP, HIB, and IPV at each administration (Base N=227,231). Vaccines additionally administered form the 7 cohorts of this study: HepB (N=321,296); PNC (pneumococcal) (N=319,420); Rota (N=10,139); HepB-PNC (N=531,516); HepB-Rota (rotavirus)(N=22,800); PNC- Rota (N=35,882); HepB-PNC-Rota (N=73,792). We produce a systematic analysis of the 7 cohorts and discover adverse outcomes associated with vaccine combinations, as well as describe adverse trends based on the increasing number of vaccines administered. All findings reported meet the highest bar of scientific scrutiny, p- value<0.0001 post-Bonferroni correction. This study’s analysis is limited to diagnoses made within 30-days of vaccination (excluding day-of vaccination) of respiratory, developmental, and suspected infections.

Author Biographies

  • Karl Jablonowski, Children's Health Defense

    Researcher at Children's Health Defense

  • Brian Hooker, Children's Health Defense

    Chief Science Officer


Burnett, E., Parashar, U., & Tate, J. (2018). Rotavirus vaccines: Effectiveness, safety, and future directions. Paediatric Drugs, 20(3), 223–233.

Fortunato, F., Martinelli, D., Lopalco, P. L., & Prato, R. (2022). Safety evaluation of the dtap5-ipv-hib-hepb vaccine: A review. Expert Opinion on Drug Safety, 21(3), 295–302.

Gagneur, A., Nowak, E., Lemaitre, T., Segura, J.-F., Delaperrière, N., Abalea, L., Poulhazan, E., Jossens, A., Auzanneau, L., Tran, A., Payan, C., Jay, N., De Parscau, L., & Oger, E. (2011). Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: The IVANHOE study. Vaccine, 29(21), 3753–3759.

Gagneur, A., Pinquier, D., & Quach, C. (2015). Immunization of preterm infants. Human Vaccines & Immunotherapeutics, 11(11), 2556–2563.

Mayr, F. B., Yende, S., & Angus, D. C. (2014). Epidemiology of severe sepsis. Virulence, 5(1), 4–11.

Mijatovic-Rustempasic, S., Immergluck, L. C., Parker, T. C., Laghaie, E., Mohammed, A., McFadden, T., Parashar, U. D., Bowen, M. D., & Cortese, M. M. (2017). Shedding of porcine circovirus type 1 DNA and rotavirus RNA by infants vaccinated with Rotarix®. Human Vaccines & Immunotherapeutics, 13(4), 928–935.

Pinkbook: Hepatitis B | cdc. (2022, September 21).

Pinkbook: Pneumococcal disease | cdc. (2022, September 21).

Roué, J.-M., Nowak, E., Le Gal, G., Lemaitre, T., Oger, E., Poulhazan, E., Giroux, J.-D., Garenne, A., & Gagneur, A. (2014). Impact of rotavirus vaccine on premature infants. Clinical and Vaccine Immunology: CVI, 21(10), 1404–1409.

Wodi, A. P. (2024). Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger—United states, 2024. MMWR. Morbidity and Mortality Weekly Report, 73.




How to Cite

Adverse Outcomes Are Increased with Exposure to Added Combinations of Infant Vaccines. (2024). International Journal of Vaccine Theory, Practice, and Research , 3(2), 1103-1111.

Similar Articles

1-10 of 49

You may also start an advanced similarity search for this article.